The management of lobular carcinoma in situ (LCIS). Is LCIS the same as ductal carcinoma in situ (DCIS)?
Date
2006-09-01ICR Author
Author
Lakhani, SR
Audretsch, W
Cleton-Jensen, A-M
Cutuli, B
Ellis, I
Eusebi, V
Greco, M
Houslton, RS
Kuhl, CK
Kurtz, J
Palacios, J
Peterse, H
Rochard, F
Rutgers, E
EUSOMA,
Type
Journal Article
Metadata
Show full item recordAbstract
Lobular carcinoma in situ was first described over 60 years ago. Despite the long history, it continues to pose significant difficulties in screening, diagnosis, management and treatment. This is partly due its multi-focal and bilateral presentation, an incomplete understanding of its biology and natural history and perpetuation of misconceptions gathered over the last decades. In this review, the working group on behalf of EUSOMA has attempted to summarise the current thinking and management of this interesting lesion.
Collections
Subject
EUSOMA
Humans
Carcinoma, Ductal, Breast
Carcinoma, Lobular
Carcinoma in Situ
Breast Neoplasms
Adult
Middle Aged
Female
Research team
Cancer Genomics
Language
eng
Date accepted
2006-03-21
License start date
2006-09
Citation
European journal of cancer (Oxford, England : 1990), 2006, 42 (14), pp. 2205 - 2211
Publisher
ELSEVIER SCI LTD
Related items
Showing items related by title, author, creator and subject.
-
Bleeding complications in patients with squamous cell carcinoma of the head and neck.
Bergamini, C; Ferris, RL; Xie, J; Mariani, G; Ali, M; et al. (WILEY, 2021-06-12)Hemorrhage in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) may be attributed to chemotherapy and local tumor irradiation. Evidence of the relationship between hemorrhage in R/M HNSCC and ... -
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study.
Psyrri, A; Fayette, J; Harrington, K; Gillison, M; Ahn, M-J; et al. (ELSEVIER, 2023-03-01)BACKGROUND: Patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) have a poor prognosis. The phase III KESTREL study evaluated the efficacy of durvalumab [programmed death-ligand 1 (PD-L1) ... -
Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases.
Frentzas, S; Simoneau, E; Bridgeman, VL; Vermeulen, PB; Foo, S; et al. (NATURE PUBLISHING GROUP, 2016-11-01)The efficacy of angiogenesis inhibitors in cancer is limited by resistance mechanisms that are poorly understood. Notably, instead of through the induction of angiogenesis, tumor vascularization can occur through the ...